SPMS was responsible for conducting tests in Portugal within the scope of the European initiative Gravitate-Health, a project aimed at empowering citizens through digital tools that help them become more active in managing their own health. The tests focused on evaluating the integration of the Gravitate Lens (G-lens®) solution into the SNS 24 application in order to evaluate how individual health data can help make the electronic product information (ePI) of medicines – patient leaflet – more tailored to the user’s individual context, with the goal of improving usability and accessibility.
The G-lens® solution allows the content of a medicine’s product leaflet to be adapted by highlighting or suppressing information based on the user’s characteristics as recorded in their health summary, without removing any information. In Portugal, this feature was applied to the “Pregnancy, breastfeeding, and fertility” section of the product leaflet of a commonly used medicine, with the aim of testing the solution and assessing how well it integrates to existing mobile health applications.
The digital test format of the patient leaflet follows the new standard proposed by the European Medicines Agency. The objective was to test a case study in which users could test out the G-lens® feature and evaluate it in terms of usability, accessibility, and perceived usefulness, with the goal of identifying potential areas for improvement and continuing to develop a citizen-focused service.
The results of the tests conducted by SPMS highlight the potential of the technology in personalising health information, promoting a more accessible and citizen-centred approach. These findings serve as a starting point for the future integration of similar solutions in national health applications, contributing to more effective and accessible access to information from reliable and regulated sources, which will be highly relevant both for public health and disease management.
Disclaimer: The Gravitate-Health project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 945334. The JU receives support from the European Union’s Horizon 2020 research and innovation programme, the European Federation of Pharmaceutical Industries and Associations [EFPIA] and Datapharm Limited. The total budget is 19.4 M € for a project duration of 60 months. Views and opinions expressed do not necessarily reflect those of the IMI nor of the European Union, EFPIA, or Datapharm Limited. Neither the European Union nor the granting authority can be held responsible for them.
